Pricing Log in Create free account

ALX Oncology Holdings Inc. (ALXO) vs AN2 Therapeutics, Inc. (ANTX)

ALX Oncology Holdings Inc. and AN2 Therapeutics, Inc. are both Biotechnology companies. ALX Oncology Holdings Inc. and AN2 Therapeutics, Inc. are of similar size ($159.7M and $150.9M). Across the 10 metrics below, AN2 Therapeutics, Inc. leads on 8 and ALX Oncology Holdings Inc. on 2.

Valuation

Metric ALXO ANTX Biotechnology median
P/E n/m n/m 10.60
P/S 64.54 n/m 9.40
P/B 1.16 2.36 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 13.96 n/m 9.02
Earnings yield (97.41%) (26.75%) (32.88%)
Free cash flow yield (45.06%) (17.14%) (23.13%)

Profitability

Metric ALXO ANTX Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.65%) (50.12%) (51.96%)
Return on assets (63.16%) (46.06%) (46.06%)
Return on invested capital (673.30%) 0.00% 0.00%

Growth

Metric ALXO ANTX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 26.36% 32.56% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALXO ANTX Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 9.71 14.32 4.97
Net debt to EBITDA 0.34 1.48 1.01

Dividend

Metric ALXO ANTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALXO ANTX Biotechnology median
Market cap 159.71m 150.94m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack